DGCI approves for phase III trial of Bharat Biotech intranasal vaccine as booster

The Subject Experts Committee (SEC) of the Drug Controller General of India (DGCI) on Wednesday granted in principle approval to Bharat Biotech to conduct Phase III superiority study and Phase III booster dose study trials for its intranasal Covid vaccine.

Related Keywords

India ,Hyderabad ,Andhra Pradesh ,Bharat ,Narendra Modi ,Experts Committee ,Subject Experts Committee ,Drug Controller General ,Bharat Biotech ,Prime Minister Narendra Modi ,Dgci ,Pproves ,Or ,Hase ,Wii ,Trial ,F ,Biotech ,Intranasal ,Vaccine ,Us ,Rooster ,News ,Ews India ,